Matthew Parris

Direttore Tecnico/Scientifico/R&S presso TRAWS PHARMA, INC.

Health Technology

Consumer Services

Posizioni attive di Matthew Parris

Società	Posizione	Inizio	Fine
TRAWS PHARMA, INC.	Direttore Tecnico/Scientifico/R&S	01/08/2018	-

Società	Posizione	Inizio	Fine
Eleison Pharmaceuticals, Inc. Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ.	Corporate Officer/Principal	-	-
AEGERION PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-
INOVIO PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-

Imperial College London

Undergraduate Degree

Distribuzione geografica

Stati Uniti	5
Regno Unito	2

Posizioni

Corporate Officer/Principal	3
Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Settori

Health Technology	5
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	2
TRAWS PHARMA, INC.	Health Technology
INOVIO PHARMACEUTICALS, INC.	Health Technology

Aziende private	2
Eleison Pharmaceuticals, Inc. Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ.	Health Technology
Aegerion Pharmaceuticals, Inc. Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA.	Health Technology

Aziende private

Health Technology